Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 28 September 2023

 
 
 
   

News

 
Thumbnail

Evidence shows more than 600 essential medicines at risk, and manufacturing in Europe will...
28 September 2023

A proposed restriction on the use of fluorinated substances across the EEA could see the widespread shut down of medicines... Read more

Thumbnail

Orphan medicines: How the draft pharmaceutical legislation proposals would impact rare disease...
22 September 2023

As currently drafted, the European Commission proposals contained in the revised legislation would discourage the development... Read more

 
 
 
   

Blogs

 

Affordability of medicines is a two-sided coin (Guest blog)
26 September 2023 - Boris Azaïs

Pharmaceutical expenditure has remained stable at around 15% of healthcare spending in most European countries over... Read more

 
 
 
   

Events

 

Are medicines affordable for health systems?
29 September 2023 (Bad Hofgastein, Austria)

The myths, the facts, and the way forward Read more

HETHICO
03 October 2023 (Brussels)

Healthcare Ethics & Compliance Conference Read more

EFPIA Day 2023: A discussion on sustainable ways to reward pharmaceutical innovation
05 October 2023 (Virtual event)

Registrations will close on Monday 2nd October at midday. Read more

JLABS Program | Non-Confidential Data Presentation as Part of Your Partnering Approach
05 October 2023 (Leiden (Netherlands) and virtually)

The program will focus on the development of pharmaceutical and digital therapeutics. Read more

 
 
 
   

Improving the Attractiveness of the Vaccines Industry in the European Union

Vaccination is one of the most successful health prevention tools, protecting against several infectious diseases. It has allowed us to eradicate smallpox, eliminate polio from nearly every region of the world and control diseases like measles, rubella and pertussis, among many others. Vaccination brings significant value not only to public health but to the economy as well, and should be viewed as an investment, rather than a cost. However, findings from a recent report, highlight several challenges faced by the vaccine industry in Europe across the value chain.

To take full advantage of the benefits that vaccination brings, we need the right environment to encourage vaccine innovation. Discover Vaccines Europe's policy recommendations. 

 
 
 
 
   

What we are reading

 
Pharma lobby says EU ban on 'forever chemicals' would halt drug production
On 27 September 2023 (Reuters)

"The entire pharmaceutical industry would no longer be able to manufacture active pharmaceutical ingredients ...... Read more

Orphan medicines: Impact of draft pharma legislation proposals
On 25 September 2023 (ThePharmaLetter)

Plans to overhaul the EU regulation on rare disease therapies risk undermining two decades of progress, a new report... Read more

IHI project GUIDE.MRD banks on better blood tests to detect cancer
On 18 September 2023 (IHI)

After undergoing surgery to remove cancer tumours, sometimes some disease gets left behind. The new IHI GUIDE-MRD... Read more